India's GLP-1 generic market will grow 40% annually through 2026

India's diabetes epidemic and price sensitivity are accelerating adoption of generic GLP-1 drugs over branded alternatives. Biocon's entry and government incentives for affordable healthcare will sustain rapid growth, outpacing global averages.

Implied probability (Yes)

75%